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Abstract
Background Chemoprevention with the polyamine-inhib-
itory regimen difluoromethylornithine (DFMO) ? sulindac
markedly reduces risk of recurrent adenoma in colorectal
adenoma patients. Obesity is associated with risk of colo-
rectal adenoma and colorectal cancer. This study investigates
how obesity influences risk of recurrent adenoma after pro-
longed treatment with DFMO ? sulindac versus placebo.
Methods Our analysis included subjects enrolled in the
phase III colorectal adenoma prevention clinical trial inves-
tigating DFMO ? sulindac versus placebo. Patients were
classified by obesity (body mass index, BMI C 30 kg/m2)
status at baseline. Pearson v2 statistic and Mann–Whitney
U test were used to compare baseline characteristics, including
rectal tissue polyamine levels. Log-binomial regression
analysis was used to determine the risk ratio (RR) of
recurrent adenomas, adjusted for covariates and an interac-
tion term for obesity and treatment.
Results The final analytic cohort was comprised of 267
patients. In separate regression models, the risk of adenoma
recurrence after treatment compared to placebo was similar
for obese (RR = 0.32, 95 % CI 15–71) and non-obese
patients (RR = 0.27, 95 % CI 15–49). No significant
interaction was detected between obesity, treatment, and
risk of colorectal adenoma in the full regression model
(pinteraction = 0.91).
Conclusions Obesity does not substantially modify the
colorectal adenoma risk reduction ascribed to DFMO ?
sulindac versus placebo.
Keywords Body mass index  BMI 
Colorectal adenoma  Chemoprevention 
Difluoromethylornithine  Obesity  Sulindac
The abstract was presented in part at the 2011 Gastrointestinal
Cancers Symposium in San Francisco, CA, 22 January 2011.
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Introduction
Polyamines are naturally occurring substances that, in
excess, are associated with colorectal carcinogenesis in
animal models [1]. In a randomized phase III trial of
colorectal adenoma (CRA) patients, the risk of CRA
recurrence was decreased by 70 % after 3 years of treat-
ment with the polyamine-inhibitory regimen difluorom-
ethylornithine (DFMO) ? sulindac compared to placebo.
These effects were shown to occur via polyamine-depen-
dent processes [2], with differential treatment outcomes
based on genetic polymorphism of ODC1 (ornithine
decarboxylase-1)—a key regulatory gene of polyamine
metabolism [3]. Numerous observational studies have
reported associations between obesity and risk of CRA or
colorectal cancer (CRC), with variable reporting of obes-
ity-associated risks based on gender, colorectal subsite, and
adenoma characteristics (e.g., number, size, histology, and
high-risk features) [4–9]. Polyamine metabolism and its
inhibition have been associated with increased adipose
tissue and weight gain in animal models. Murine experi-
ments reveal that polyamine inhibition via knockout of
spermidine spermine acetyltransferase, SSAT (a gene
encoding SSAT, which is responsible for polyamine acet-
ylation and subsequent cellular polyamine export), results
in deceased fatty acid catabolism, increased tissue adipose
content, and increased weight gain [10]. These findings
indicate potential links between obesity and polyamine
inhibition in humans. Polyamines are derived from dietary
sources in humans (meats, corn, peas, grapefruit juice)
[11]. However, potential relationships between energy
balance and polyamine-related colorectal carcinogenesis
have not been described in humans. Here, we examine
whether obesity modifies the adenoma risk reduction con-
ferred by polyamine-inhibitory treatment among colorectal
adenoma patients.
Materials and methods
The parent study was a randomized, double-blind, placebo-
controlled multi-site clinical trial to determine the effect of
DFMO ? sulindac on CRA recurrence [12]. Eligible
patients were between 40 and 80 years of age with a his-
tory of C1 resected adenoma (C3 mm) within 5 years
before study entry. All patients underwent colonoscopy and
removal of any preexisting polyps within 6 months of
study entry. Body mass index (BMI) was calculated with
direct measurement of each participant’s height and
weight. The proportion of obese (BMI C 30 kg/m2) versus
non-obese (BMI \ 30 kg/m2) patients was similar between
screened (34 % vs. 66 %), enrolled (33 % vs. 67 %), and
non-enrolled participants (40 % vs. 60 %). The study was
approved by the University of California-Irvine Institu-
tional Review Board (# 2002–2261).
In the parent trial, a total of 375 subjects were randomized;
planned treatment duration was 36 months. At the second
interim analysis, the study was halted by the Data Safety and
Monitoring Board since clinical efficacy endpoints were
achieved. For the present analysis, data were obtained from
all 267 patients completing end-of-study colonoscopies. The
primary objective of the present study was to determine
whether obesity modifies the effect of DFMO ? sulindac
(vs. placebo) on CRA recurrence. Two categories were
defined by BMI status including a non-obese and obese
group. For the comparisons of baseline characteristics of
patients in the obese versus non-obese groups, dichotomous
variables were created to represent factors previously asso-
ciated with increased risk of advanced metachronous ade-
noma. These included the presence of proximal (right-sided)
lesions, defined as those in the transverse colon, right colon,
and cecum; large adenomas, defined as C10 mm in size;
multiple adenomas (3 or more); adenomas with advanced
histology (i.e., villous or tubulovillous features, high-grade
dysplasia, and carcinoma-in situ); and high-risk lesions,
which included either advanced adenomas, multiple adeno-
mas, or those[10 mm in size.
Statistical analysis
Comparisons of demographic, clinical, and pathological
variables were performed using Pearson v2 statistic for
nominal variables and Mann–Whitney U test for continuous
variables that were not normally distributed: age, tissue
polyamines, and number of adenomas. The risk ratio of
development of any recurrent adenoma was assessed by log-
binomial regression, with adjustment for treatment group,
obesity, age, aspirin use, and a term representing the inter-
action of obesity and treatment group. Aspirin use was
included in the model as this was a stratification factor in the
parent trial and used in the primary efficacy analyses of that
trial [12]. Age was included in the full regression model
(containing obese and non-obese patients) due to the baseline
differences observed in the obese versus non-obese groups
and excluded from the multivariate regression models that
were restricted to either the obese group or non-obese group.
Seventy-two patients had developed metachronous adeno-
mas in the final dataset. Statistical analyses were conducted
using SAS 9.2 statistical software (SAS Inc., Cary, NC).
Results
Baseline characteristics of the final analytic cohort are
presented in Table 1. The median age of all participants was
1740 Cancer Causes Control (2012) 23:1739–1744
123
60.8 years. The median BMI was 28.8 kg/m2, with a range
of 17.0–52.4 kg/m2. The non-obese group consisted of
approximately twice as many patients as the obese group.
The obese group was significantly younger than the non-
obese group: 59.0 versus 61.9 years (p = 0.004). No sig-
nificant differences were observed between obesity groups
for gender, ethnicity, aspirin use, treatment received, or
baseline rectal tissue polyamine contents. Significant
baseline differences in adenoma characteristics between
obese and non-obese patients were observed.
Among 86 obese patients, 23 patients had recurrent
adenomas at the end-of-study, including 6 recurrences
among 43 patients (14 %) in the DFMO ? sulindac group,
and 17 recurrences among 43 patients (40 %) in the pla-
cebo group. The risk ratio of adenoma recurrence after
treatment (compared to placebo, as a referent group)
among obese patients was 0.32, 95 % confidence interval,
CI = 0.15–0.71 (Table 2). Among the 181 non-obese
patients, 49 patients had recurrent adenomas at the end-of-
study, including 11 recurrences among 95 patients (12 %)
in the DFMO ? sulindac group, and 38 recurrences among
86 patients (44 %) in the placebo group. Among non-obese
patients, the risk ratio of adenoma recurrence after treat-
ment (compared to placebo, as a referent group) was 0.27,
with 95 % CI = 0.15–0.49 (Table 2). In the full regression
model including all 267 subjects, with adjustment for
treatment group, obesity, age, aspirin use, and a term rep-
resenting the interaction of obesity and treatment, no sig-
nificant interaction was noted between treatment and
obesity with regard to adenoma recurrence (p = 0.91).
Main effects for obesity were not significant in the full risk
models when analyzed as a dichotomous variable (obese
vs. non-obese): RR = 1.20, 95 % CI 0.72–2.02; p = 0.49,
or as a continuous variable (BMI): RR = 1.01, 95 % CI
0.98–1.05; p = 0.45. Further analyses based on risk of
multiple or advanced adenomas were not performed due to
a low number of events in the treatment group.
Discussion
Here, we report that obesity does not modify the CRA risk
reduction previously ascribed to DFMO ? sulindac versus
placebo. We observed a 68 % reduction in recurrent
CRA among obese patients (vs. 73 % reduction among
non-obese patients) after prolonged administration of
DFMO ? sulindac compared with placebo. Obesity itself
was not found to be associated with recurrent CRAs, a
finding congruent with some—but not all previous reports
[4, 13, 14]. Obesity was associated with several baseline
adenoma characteristics that are risk factors for advanced
adenoma recurrence; however, the trial was not designed to
prospectively stratify patients by obese status in the
randomization process. In contrast to results from mouse
model experiments noting associations between obesity
and polyamine levels [10], we did not observe any differ-
ences in rectal tissue polyamine levels among trial partic-
ipants based on obesity status at baseline (Table 1).
Inconsistencies in the literature regarding associations
between obesity and risk of CRA or CRC may be partly
related to obesity definitions. While many studies have
utilized BMI as an indicator of obesity, other measures of
obesity are studied (e.g., waist circumference, waist-to-hip
ratio, visceral adipose tissue). Abdominal obesity has been
shown to be linked to insulin resistance and hyperinsuli-
nemia [15], which has been suggested to underlie the
association of obesity and CRA. In vitro studies have
shown that insulin promotes cell growth in colonic mucosa
and in colon carcinoma cells [16]. Epidemiological data
indicate that metabolic syndrome, a cluster of metabolic
abnormalities including insulin resistance and central
obesity, as well as insulin-dependent Type II diabetes, are
biological risk factors for the development of CRAs and
CRCs [17]. Insulin levels and insulin-like growth factor-I
are positively associated with CRA incidence, especially
advanced adenomas. Interestingly, the same study found no
association between visceral adipose tissue and BMI and
adenoma risk [13]. Therefore, obesity may be acting as a
surrogate risk factor not only for hyperinsulinemia, but also
for other potential underlying factors such as low physical
activity or high-risk dietary patterns [18]. As these factors
typically do not exist in isolation, it remains difficult to
determine to what degree each of these factors plays a role
in colorectal adenoma and cancer risk.
A recent Japanese study investigated how the adipokines
mediate associations between obesity and CRC [19]. An
inverse association between adiponectin level and CRA was
found, whereas a positive association of leptin was noted.
Adiponectin may exert anticarcinogenic effects on the large
intestine by interfering with leptin, whereas leptin could
conversely exert carcinogenic effects under conditions of
lower adiponectin levels. Since adipokines play an important
role in insulin resistance [20], future studies on the interac-
tions between adipokines and the insulin pathway may better
elucidate underlying mechanisms. A National Cancer Insti-
tute-sponsored multi-institutional phase IIa clinical bio-
marker trial investigating adipokines and other relevant
biomarkers pre- and post-metformin treatment in obese CRA
patients is currently ongoing at the University of California
Irvine, with results anticipated in 2013 [21].
Several limitations of this study must be acknowledged.
Our analysis was performed using data from the controlled
setting of a phase III trial with a relatively small sample
size. The recurrence analysis was limited by the over-
whelming effect of treatment in approximately half of the
study population (i.e., some of the effects of obesity, if
Cancer Causes Control (2012) 23:1739–1744 1741
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Table 1 Clinicopathologic baseline characteristics of the final analytic cohort
All
(n = 267)
BMI \ 30
(n = 181)
BMI C 30
(n = 86)
p*
Age (years)
Median 60.8 61.9 59.0 0.004a
Range 41.4–78.8 41.4–78.8 42.4–73.8
Sex
Male 202 (75.7 %) 138 (76.2 %) 64 (74.4 %) 0.74
Female 65 (24.3 %) 43 (23.8 %) 22 (25.6 %)
Ethnicity
Asian/Pacific Islander 12 (4.5 %) 11 (6.1 %) 1 (1.1 %) 0.14
Black 8 (3.0 %) 5 (2.8 %) 3 (3.5 %)
Hispanic 19 (7.1 %) 9 (5.0 %) 10 (11.6 %)
White 224 (83.9 %) 153 (84.5 %) 71 (82.6 %)
Other 4 (1.5 %) 3 (1.7 %) 1 (1.1 %)
Aspirin use
Yes 103 (38.6 %) 74 (40.9 %) 29 (33.7 %) 0.26
No 164 (61.4 %) 107 (59.1 %) 57 (66.3 %)
BMI (kg/m2)
Median 28.8 – – –
Range 17.0–52.4 – –
95 % CI 21.9–39.3 – –
Treatment
DFMO/sulindac 138 (51.7 %) 95 (52.5 %) 43 (50.0 %) 0.70
Placebo 129 (49.3 %) 86 (47.5 %) 43 (50.0 %)
Tissue polyaminesb (nmol/mg)c
Putrescine
Median 0.49 0.5 0.49 0.58a
Range 0.01–5.29 0.01–5.29 0.01–3.27
Spermidine
Median 2.06 2.07 2.05 0.93a
Range 0.76–11.45 0.76–9.18 1.05–11.45
Spermine
Median 7.07 7.07 7.12 0.43a
Range 2.29–34.10 2.29–28.31 3.88–34.10
Spermidine:spermine Ratio
Median 0.3 0.3 0.29 0.33a
Range 0.19–0.98 0.19–0.98 0.20–0.76
Number of adenomasb
Mean 2.4 (± 2.0 SD) 2.2 (± 1.6 SD) 3.0 (± 2.6 SD) 0.006
Median 2 2 2
95 % CI 1–6 1–6 1–8
Adenoma size (mm)
\10 183 (68.5 %) 136 (75.1 %) 47 (54.6 %) 0.0008
C10 84 (31.5 %) 45 (24.9 %) 39 (45.4 %)
Multiple adenomasb
\3 182 (68.9 %) 132 (73.7 %) 50 (58.8 %) 0.01
C3 82 (31.1 %) 47 (26.3 %) 35 (41.2 %)
Advanced adenoma histologyd
Yes 46 (17.2 %) 24 (13.3 %) 22 (25.6 %) 0.013
No 221 (82.8 %) 157 (86.7 %) 64 (74.4 %)
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present, may have been minimized). Additionally, we were
not able to test other measures of obesity (e.g., central
obesity or percentage body fat), which may have resulted
in different outcomes, and did not account for other rele-
vant lifestyle or hormonal factors. It is possible that dif-
ferences in drug metabolism may occur based on the
volume of distribution (which is increased in patients with
large amounts of adipose tissue) or under-dosing due to a
particular fixed-dose regimen utilized here. For example, in
oncology, drug dosing of obese patients has been identified
as a potential factor for the observed poor outcomes among
obese cancer patients. In obese cancer patients, it is
believed that fixed drug dosing or dose ‘‘capping’’ (i.e.,
limiting the body surface area to a pre-specified maximum
number) may result in inadequate drug delivery [22]. It is
important to note that the tissue polyamine contents eval-
uated here refer to steady-state levels of specifically rectal
mucosal polyamine contents. Differences in adipose tissue
polyamine contents were not addressed in our study, which
represents a limitation of the analysis. Additionally, we did
not examine total polyamine flux—which may be impor-
tant in understanding polyamine effects on metabolism.
Our analysis suggests that obesity does not substantially
modify CRA risk reduction after treatment with DFMO ?
sulindac compared with placebo. This has implications for
therapeutic prevention of CRAs, since a key goal of cancer
prevention clinical trials is to refine the risk:benefit, and
risk:risk profile of chemopreventive agents. The large risk
reduction afforded to CRA patients receiving DFMO ?
sulindac as compared to placebo in the parent trial appears
to occur regardless of whether or not patients are obese.
Potential benefits of lifestyle modifications on colorectal
carcinogenesis in general (including control of obesity,
increasing physical activity, and specific dietary modifi-
cations) are clearly relevant and beyond this scope of this
manuscript.
Table 2 Colorectal adenoma recurrence risk* after treatment with DFMO ? sulindac versus placebo, by obesity status at baseline
Non-obese patients (n = 181) Obese patients (n = 86)
n Risk ratio (95 % confidence interval) p n Risk ratio (95 % confidence interval) p
Recurrent adenoma events
Any adenoma 49 0.27 (0.15–0.49) \0.0001 23 0.32 (0.15–0.71) 0.005
Risk ratios indicate the effect of DFMO ? sulindac compared with placebo (as a referent value) on recurrent colorectal adenomas
* Relative risk estimation by log-binomial regression. Likelihood ratio test p values are reported. Risk ratios indicate risk of metachronous
adenoma after treatment with DFMO ? sulindac versus placebo (referent group). All risk ratios are adjusted for aspirin intake
Table 1 continued
All
(n = 267)
BMI \ 30
(n = 181)
BMI C 30
(n = 86)
p*
Locatione
Proximalf 99 (37.2 %) 78 (43.3 %) 21 (24.4 %) 0.003
Distalg 167 (62.8 %) 102 (56.7 %) 65 (75.6 %)
High-risk adenomash
Yes 144 (53.9 %) 82 (45.3 %) 62 (72.1 %) \0.0001
No 123 (46.1 %) 99 (54.7 %) 24 (27.9 %)
* p values indicate comparisons between the obese and non-obese groups
a Mann–Whitney U test
b Data missing from three patients
c nmol polyamine per milligram protein
d Includes adenomas with villous or tubulovillous features, high-grade dysplasia, or carcinoma-in situ
e Data missing from one patient
f Includes the cecum, right colon, and transverse colon
g Includes the left colon and rectum
h Includes adenomas[1 cm in size, multiple adenomas (3 or more at baseline), or those with the following histologic characteristics: villous or
tubulovillous features, high-grade dysplasia, or carcinoma-in situ
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